Setting the record straight
By Martin H. Johnson,
Reproductive BioMedicine Online
| 12. 01. 2016
This editorial comments on a paper from Chen et al. (2016)), published in this issue of RBM Online, in an attempt to set the record straight after some shoddy scientific journalism. The paper describes the long-term outcomes of experimental treatments involving ooplasmic transfers conducted between 1996 and 2001 at Saint Barnabas Medical Centre, Livingston, New Jersey, USA (Barritt et al., 2001a). It is timely to report these findings in light of (i) a recent report of the birth of a baby after ‘mitochondrial transfer’, and (ii) because the Human Fertilisation and Embryology Authority (HFEA) in the UK is deciding whether to issue a license for treatment by mitochondrial transfer (http://www.hfea.gov.uk/10363.html).
First, the report of the birth of a baby after meiotic metaphase II spindle transfer to alleviate mitochondrial disease came not in a standard journal article, but in the form of an abstract submitted to the recent American Society for Reproductive Medicine (ASRM) meeting (Zhang et al., 2016a). In choosing this route, the authors have unfortunate form – the same authors having used the same...
Related Articles
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
Alice Wong, founder of the Disability Visibility Project, MacArthur Genius, liberationist, storyteller, writer, and friend of CGS, died on November 14. Alice shone a bright light on pervasive ableism in our society. She articulated how people with disabilities are limited not by an inability to do things but by systemic segregation and discrimination, the de-prioritization of accessibility, and the devaluation of their lives.
We at CGS learned so much from Alice about disability justice, which goes beyond rights...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...